BLOG

Could You Help Us Fight Alzheimer's Disease?

Alzheimer’s is linked to the build-up of an abnormal protein in the brain called amyloid beta. Early on, this process doesn’t cause any obvious symptoms. But later, cognitive problems such as memory loss may emerge. The question is, could targeting amyloid beta prevent this?

 

To answer this question and more, we need your help. We’re looking for people to join a clinical study called SKYLINE. SKYLINE will study an investigational drug that targets amyloid beta. To take part, you must:

 

•Be 60–80 years old

•Not be experiencing any memory or thought-processing problems

•Not be diagnosed with Mild Cognitive Impairment (MCI), Alzheimer’s or dementia

•Be interested in learning about your risk of developing Alzheimer’s

•Able to join with a study partner

 

The study partner will provide emotional and practical support to the participant for the duration of the study.

 

If you’re interested in taking part, we’d first conduct some screening assessments to make sure that you and the study are a good fit. For example, we’d measure the amount of amyloid beta in your brain as only people with a certain level can join SKYLINE. If you’re eligible, you’ll then be invited to join the study.

 

If you join, you’ll receive subcutaneous (under the skin) injections containing the study medication (either the investigational drug or a placebo). A placebo looks just like the investigational drug but contains no active ingredients.

 

For the first 9 months of SKYLINE, the amount of study medication will gradually increase until it reaches the target dose. After 9 months, you’ll then follow your chosen study treatment schedule (one injection of study medication every week, or two injections, at the same time, every two weeks), for the remaining 43 months (about 3.5 years).* This may sound like a long time, but it can be many years before someone with rising levels of amyloid beta begins to display any outward signs. Please be aware that participants who experience Alzheimer’s symptoms (and have reached the target dose of study medication) will be given the investigational drug even if they were given the placebo before.

 

If this study sounds interesting to you or someone you know, please contact Bradenton Research Center for a confidential and no-obligation chat. We’re particularly interested in hearing from people with a family history of dementia, which is why we thought you may be interested. Of course, participation is entirely voluntary. It’s also worth noting that all study medication and assessments would be provided to you at no cost and health insurance is not required.

 

Thank you for your time.

 

*Any participant who develops Alzheimer’s during the study and is switched to the investigational drug may temporarily receive their investigational drug more frequently than their chosen dosing schedule.